HMOX1 and cardiomyopathy: Interestingly, blocking either HO-1 or ferroptosis significantly decreased doxorubicin-induced cardiomyopathy and heart failure, similar to the protective effects of iron chelation with dexrazoxane [186] (Figure 4).